Gilde Healthcare anchors $103.5 million public offering by Affimed - Gilde Healthcare

Gilde Healthcare anchors $103.5 million public offering by Affimed

April 21, 2022
Utrecht (the Netherlands)

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed.

“We are excited to team up with the excellent team at Affimed, who are front-runners in engaging the innate immune system to fight some of the most difficult-to-treat cancers,” said Joep Muijrers, General Partner at Gilde Healthcare and responsible for Gilde’s public investment franchise. “We are proud to add Affimed to our expanding portfolio, and look forward to closely working with them in the years to come”.

Pieter van der Meer, Managing Partner of Gilde Healthcare commented “We followed Affimed for many years and are convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring the public offering we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.”

The full text of the announcement from Affimed can be found here:
Affimed announces closing of public offering of common shares and full exercise of underwriters’ option to purchase additional shares – Affimed.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit www.gildehealthcare.com.

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
April 22, 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
April 1, 2025